Emerging data suggest this peptide, a dual agonist targeting both incretin and GIP , appears to offer a promising development for obesity treatment. Early human investigations have indicated considerable reductions in abdominal fat , possibly surpassing existing body composition therapies . Nevertheless , additional study is necessary to completely